Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Santarus Inc Issues FY 2013 Revenue And Net Income Guidance; EBITDA And EPS Guidance Above Analysts' Estimates
Santarus Inc announced that for fiscal 2013, it expects total revenues of approximately $320 million to $325 million, net income of approximately $50 million to $54 million, and diluted EPS of $0.63 to $0.68, adjusted EBITDA, or non-GAAP adjusted earnings, of approximately $73 million to $79 million and non-GAAP adjusted diluted EPS of $0.92 to $1.00. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $323 million, net income of $50 million, EBITDA of $60 million and EPS of $0.70 for fiscal 2013.
Latest Developments for Santarus Inc
- Santarus Inc and Pharming Group NV Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
- Santarus Inc Raises FY 2013 Guidance
- Santarus Inc and Pharming Group NV Announce Submission of RUCONEST Biologics License Application to FDA
- Santarus Inc Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study
- Share this
- Link this
- Digg this


Follow Reuters